Cochrane · systematic review · CD011649
Management of people with intermediate‐stage hepatocellular carcinoma
Roccarina, D, Majumdar, A, Thorburn, D, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
1
No studies
5
Included studies
NR
No studies 5 · 83.3%Ungraded 0 · 0%Very low 1 · 16.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Chemotherapy versus no chemotherapy for intermediate‐stage hepatocellular carcinoma
Population: people with intermediate‐stage hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (at maximal Chemotherapy vs no chemotherapy | HR 0.85 [0.6, 1.18] | 2 studies · 412 participants | Very low Downgraded: risk of bias |
Short‐term and medium‐term mortality Chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
Adverse events Chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
Quality of life Chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
Disease recurrence Chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
Length of hospital stay Chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |